首页> 外文期刊>Nature Communications >Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment
【24h】

Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment

机译:可溶性IL-33受体sST2通过修饰肿瘤微环境抑制大肠癌的恶性生长

获取原文
       

摘要

Interleukin-33 (IL-33) was recently shown to be involved in the inflammatory tumour microenvironment and the progression of colorectal cancer (CRC). We report here that the expression level of sST2, a soluble form of the IL-33 receptor (ST2L), is inversely associated with the malignant growth of CRC. sST2 is downregulated in high-metastatic cells compared with low-metastatic human and mouse CRC cells. Knockdown of sST2 in low-metastatic cells enhances tumour growth, metastasis and tumour angiogenesis, whereas its overexpression in high-metastatic cells suppresses these processes. Circulating and intratumourally administered sST2-Fc fusion protein reduce tumour growth, metastatic spread and tumour angiogenesis in mice bearing high-metastatic CRC. Mechanistically, sST2 suppresses IL-33-induced angiogenesis, Th1- and Th2-responses, macrophage infiltration and macrophage M2a polarization. In conclusion, we show that sST2 negatively regulates tumour growth and the metastatic spread of CRC through modification of the tumour microenvironment. Thus, the IL-33/ST2L axis may be a potential therapeutic target in CRC.
机译:最近显示白介素33(IL-33)参与炎性肿瘤微环境和结直肠癌(CRC)的进展。我们在这里报告,sST2,IL-33受体(ST2L)的可溶性形式的表达水平与CRC的恶性增长呈负相关。与低转移的人和小鼠CRC细胞相比,sST2在高转移的细胞中被下调。在低转移细胞中抑制sST2可以促进肿瘤生长,转移和肿瘤血管生成,而在高转移细胞中过度表达可抑制这些过程。循环和肿瘤内给药的sST2-Fc融合蛋白可降低携带高转移性CRC的小鼠的肿瘤生长,转移扩散和肿瘤血管生成。从机制上讲,sST2抑制IL-33诱导的血管生成,Th1和Th2反应,巨噬细胞浸润和巨噬细胞M2a极化。总之,我们表明sST2通过修饰肿瘤微环境负调控肿瘤的生长和CRC的转移扩散。因此,IL-33 / ST2L轴可能是CRC中潜在的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号